The aim of this study is to determine whether oral losartan is effective in the treatment of diabetic macular edema (DME) as an adjuvant for intravitreal bevacizumab (IVB).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
57
Farabi Eye Hospital
Tehran, Tehran Province, Iran
difference in ETDRS best-corrected visual acuity (BCVA) between arms
Time frame: Within 6 months from therapy
Difference in frequency of intravitreal Bevacizumab injection between arms
Time frame: Within 6 months from therapy
change in central macular thickness(measured by spectral domain optical coherence tomography)
Time frame: Within 6 months from therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.